Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Factor XIa and Thrombin Generation Are Elevated in Patients with Acute Coronary Syndrome and Predict Recurrent Cardiovascular Events.

Loeffen R, van Oerle R, Leers MP, Kragten JA, Crijns H, Spronk HM, Ten Cate H.

PLoS One. 2016 Jul 15;11(7):e0158355. doi: 10.1371/journal.pone.0158355. eCollection 2016.

2.

Markers of thrombin generation are associated with myocardial necrosis and left ventricular impairment in patients with ST-elevation myocardial infarction.

Hansen CH, Ritschel V, Halvorsen S, Andersen GØ, Bjørnerheim R, Eritsland J, Arnesen H, Seljeflot I.

Thromb J. 2015 Sep 22;13:31. doi: 10.1186/s12959-015-0061-1. eCollection 2015.

3.

Effects of Rivaroxaban on Platelet Activation and Platelet-Coagulation Pathway Interaction: In Vitro and In Vivo Studies.

Perzborn E, Heitmeier S, Laux V.

J Cardiovasc Pharmacol Ther. 2015 Nov;20(6):554-62. doi: 10.1177/1074248415578172. Epub 2015 Apr 6.

4.

Clinical use of rivaroxaban: pharmacokinetic and pharmacodynamic rationale for dosing regimens in different indications.

Trujillo T, Dobesh PP.

Drugs. 2014 Sep;74(14):1587-603. doi: 10.1007/s40265-014-0278-5. Review. Erratum in: Drugs. 2014 Oct;74(15):1837.

5.

The "dual-pathway" strategy after acute coronary syndrome: rivaroxaban and antiplatelet agents in the ATLAS ACS 2-TIMI 51 trial.

Cohen M, Iyer D.

Cardiovasc Ther. 2014 Oct;32(5):224-32. doi: 10.1111/1755-5922.12083. Review.

6.

Rivaroxaban in patients with a recent acute coronary syndrome event: integration of trial findings into clinical practice.

Shivu GN, Ossei-Gerning N.

Vasc Health Risk Manag. 2014 May 12;10:291-302. doi: 10.2147/VHRM.S59420. eCollection 2014. Review.

7.

The Utility of Platelet and Coagulation Testing of Antithrombotics: Fusing Science with Patient Care.

Jennings LK, Kotha J.

Drug Dev Res. 2013 Dec;74(8):587-593. Epub 2013 Nov 15.

8.

New oral anticoagulant agents after ACS.

Sinnaeve PR, Adriaenssens T, Höchtl T, Huber K.

Eur Heart J Acute Cardiovasc Care. 2012 Apr;1(1):87-93. doi: 10.1177/2048872612442914.

9.

Potential role of rivaroxaban in patients with acute coronary syndrome.

Fitchett DH.

Drug Des Devel Ther. 2012;6:349-57. doi: 10.2147/DDDT.S30342. Epub 2012 Nov 22. Review.

10.

Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Garcia DA, Baglin TP, Weitz JI, Samama MM.

Chest. 2012 Feb;141(2 Suppl):e24S-e43S. doi: 10.1378/chest.11-2291. Review. Erratum in: Chest. 2012 May;141(5):1369. Dosage error in article text. Chest. 2013 Aug;144(2):721. Dosage error in article text.

11.

Systemic blood coagulation activation in acute coronary syndromes.

Undas A, Szułdrzyński K, Brummel-Ziedins KE, Tracz W, Zmudka K, Mann KG.

Blood. 2009 Feb 26;113(9):2070-8. doi: 10.1182/blood-2008-07-167411. Epub 2008 Oct 17.

12.

The antithrombotic profile of aspirin. Aspirin resistance, or simply failure?

Altman R, Luciardi HL, Muntaner J, Herrera RN.

Thromb J. 2004 Jan 14;2(1):1. No abstract available.

13.

Cost effectiveness of extended treatment with low molecular weight heparin (dalteparin) in unstable coronary artery disease: results from the FRISC II trial.

Janzon M, Levin LA, Swahn E; Fragmin and Fast Revascularisation during Instability in Coronary Artery Disease II Investigators.

Heart. 2003 Mar;89(3):287-92.

14.

The primacy of clinical effectiveness for cost effectiveness analysis.

Casserly IP, Topol EJ.

Heart. 2003 Mar;89(3):249-50. No abstract available.

15.

Critical review of unstable angina and non-ST elevation myocardial infarction.

Sheridan PJ, Crossman DC.

Postgrad Med J. 2002 Dec;78(926):717-26. Review.

16.

New advances in the management of acute coronary syndromes: 4. Low-molecular-weight heparins.

Ageno W, Turpie AG.

CMAJ. 2002 Apr 2;166(7):919-24. Review. No abstract available.

17.

Arterial indications for the low molecular weight heparins.

Ageno W, Huisman MV.

Curr Control Trials Cardiovasc Med. 2001;2(5):233-239.

18.
19.

Management of unstable angina based on considerations of aetiology.

Braunwald E.

Heart. 1999 Sep;82 Suppl 1:I5-7. Review. No abstract available.

20.

Sleep apnoea in ischaemic heart disease: differences between acute and chronic coronary syndromes.

Moruzzi P, Sarzi-Braga S, Rossi M, Contini M.

Heart. 1999 Sep;82(3):343-7.

Supplemental Content

Support Center